Table 2.
Patient characteristics.
| n or Value | % | ||
|---|---|---|---|
| Age | mean/median | 62/66 years | |
| range | 24–83 years | ||
| FIGO Stage | I or II | 0 | 0.0% |
| III | 34 | 70.8% | |
| IV | 14 | 29.2% | |
| pT | pT2 | 5 | 10.4% |
| pT3 | 43 | 89.6% | |
| pN | pN0 | 6 | 12.5% |
| pN1 | 31 | 64.6% | |
| Nx | 11 | 22.9% | |
| cM | cM0 | 34 | 70.8% |
| cM1 | 14 | 29.2% | |
| Primary Tumor Site | Ovarian | 39 | 81.3% |
| Fallopian Tube | 6 | 12.5% | |
| Peritoneal | 3 | 6.3% | |
| Histological Subtype | Serous | 44 | 91.7% |
| Other | 4 | 8.4% | |
| Grading | G1/G2 | 2 | 4.2% |
| G3 | 46 | 95.8% | |
| Ascites | yes | 40 | 83.3% |
| no | 8 | 16.7% | |
| Macroscopic Residual Tumor after Surgery | None | 35 | 72.9% |
| <1 cm | 6 | 12.5% | |
| >1 cm | 7 | 14.6% | |
| First-Line-Treatment | C | 4 | 8.3% |
| C + P | 15 | 31.3% | |
| C + P + B | 25 | 52.1% | |
| None | 4 | 8.3% | |
| Relapse after Chemotherapy | <6 months | 2 | 4.2% |
| 6–12 months | 12 | 25.0% | |
| >12 months | 28 | 58.3% | |
| none or non-sufficient chemotherapy | 6 | 12.5% |
Legend: n: number of patients, Nx: no evaluation of lymph node status, C: carboplatin, P: paclitaxel, B: bevacizumab.